Patents by Inventor Yong Hyub LEE

Yong Hyub LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL DEUTERIUM-SUBSTITUTED PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20230114177
    Abstract: A novel deuterium-substituted pyrimidine derivative compound of Formula 1, or a pharmaceutically acceptable salt thereof is disclosed. A composition containing the compound and uses thereof in treating cancer are also disclosed.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 13, 2023
    Applicant: ONCOBIX CO., LTD.
    Inventors: Sung-Eun KIM, Sunho LEE, Rengasamy RAJESH, Yong Hyub LEE, Yun Jeong KONG
  • PYRIMIDINE DERIVATIVE INHIBITING GROWTH OF CANCER CELL AND MEDICINAL USE THEREOF
    Publication number: 20220227781
    Abstract: The present invention provides novel pyrimidine derivative compounds inhibiting growth of cancer cells and pharmaceutically acceptable salts thereof. The present invention provides a pharmaceutical composition comprising these compounds or pharmaceutically acceptable salts. The present invention also provides a medical use for treatment of lung cancer, characterized by using these pyrimidine derivative compounds and pharmaceutically acceptable salts thereof as an active ingredient. The present invention also provides a method for treatment of lung cancer comprising administering an effective dose of compounds according to the present invention, salts thereof or a composition comprising them.
    Type: Application
    Filed: June 19, 2020
    Publication date: July 21, 2022
    Inventors: Hyung-Chul RYU, Jae-Sun KIM, Sung-Eun KIM, Sun-Ho LEE, Yong-Hyub LEE
  • NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
    Publication number: 20220204492
    Abstract: The present invention provides a novel compound represented by Chemical Formula 1 or a salt thereof and a pharmaceutical composition for treating lung cancer containing same. A pyrimidine derivative compound represented by Chemical Formula 1 effectively inhibits the growth of cancer cells with an ALK mutation and an EGFR mutation, thereby being effectively usable in the treatment of lung cancer.
    Type: Application
    Filed: October 8, 2020
    Publication date: June 30, 2022
    Applicant: ONCOBIX CO., LTD.
    Inventors: Sung-Eun KIM, Sunho LEE, Rengasamy RAJESH, Yong Hyub LEE, Sung Tak HONG